Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Advanced Gastric Cancer Clinical Trial

Official title:

A Phase I/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Patients With Advanced Gastric Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00845884
• Other study ID #: AVDCF-2008
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• First received: February 16, 2009
• Last updated: February 16, 2009
• Start date: February 2009
• Est. completion date: December 2012

Study information

• Verified date: February 2009
• Source: Rabin Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

In spite of multiple attempts to improve the efficacy of first-line chemotherapy in advanced gastric cancer, the progress that has been achieved so far is rather limited, and many investigators are exploring newer regimens.A combination of decetaxel (Taxotere) with Cisplatin and 5-fluorouracil (5FU) is considered one of the most effective regimens in this disease. However, it is associated with significant toxicity which avoided its general adaptation by the medical community. The current study is exploring a newer way to administer these three drugs, hopefully making the regimen more comfortable, less toxic and maybe even more effective. We will do this by changing the dose and timing of Taxotere and Cisplating, by replacing protracted infusion of 5FU with tablets of Capecitabine (Xeloda) and by adding the anti-angiogenic drug, Bevacizumab (Avastin), which had shown encouraging results in this disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 49
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients above 18 years of age at the time of enrollment.

2. Histologically confirmed previously untreated metastatic or unresectable adenocarcinoma of the stomach.

3. Patients must have at least one measurable lesion (measuring >10mm in standard CT or >5mm in spiral CT).

4. Adequate organ function.

5. Life expectancy of at least three months.

6. Patients must have an ECOG Performance Status of 0 or 1.

7. Signed written informed consent to participate in the study.

Exclusion Criteria:

1. Participation in an investigational trial within 30 days of the screening visit.

2. Known allergy or any other adverse reaction to any of the study drugs or to any related compound.

3. Prior anti-angiogenic treatment, chemotherapy or radiotherapy for advanced disease. Patients will be eligible if they had received adjuvant chemotherapy or radiotherapy more than 12 months prior to enrollment.

4. Prior treatment with drugs included in the investigational regimen. Prior use of 5-fluorouracil in the adjuvant setting is allowed.

5. Significant bleeding by the primary tumor (in unoperated patients).

6. Clinically significant (i.e. active) cardiovascular disease. This includes, but is not limited to, the following examples:

• Cerebrovascular accidents (up to 6 months prior to randomization)

• Myocardial infarction (up to 1 year prior to randomization).

• Uncontrolled hypertension (above 150/100 mmHg) while receiving chronic medication

• Unstable angina

• New York Heart Association (NYHA) Grade II or greater congestive heart failure.

• Serious cardiac arrhythmia requiring medication.

• Clinically significant ECG findings. Patients who suffer from serious cardiac arrhythmia requiring medication can enter the study only if they are considered to be in a stable condition regarding both the arrhythmia and their medication. Patients with pacemakers are allowed to enter the study only if they are considered as being in a stable condition. In case of doubt, the investigator should obtain a consultation with a local cardiologist.

7. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, not fully healed wounds, or anticipation of the need for major surgical procedure during the course of the study.

8. Severe co-morbid conditions including uncontrolled diabetes or hypertension, cerebral vascular disease or uncontrolled infection.

9. Fertile subjects who are not willing to use an acceptable method of contraception during the treatment period and for 28 days following completion of treatment

10. For women of child-bearing potential: a positive pregnancy test at screening or breast-feeding.

11. History of prior malignancy (other than non-melanoma skin cancer, in-situ cervical cancer, or superficial transitional cell bladder cancer) in the last 5 years prior to enrollment.

12. Clinically significant hearing loss.

13. Patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication.

14. Known peripheral neuropathy of CTCAE v 3.0 Grade 1 or more.

15. Organ allografts requiring immunosuppressive therapy.

16. Serious, non-healing wound, ulcer, or bone fracture.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Docetaxel, Cisplatin, Capecitabine, Bevacizumab
Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days. Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days. Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days. Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days.

Locations

Country	Name	City	State
Israel	Davidoff Cancer Center, Rabin Medical Center	Petach Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response rate		2/2009-12/2012	No
Secondary	Safety, PFS, overall survival		2/2009-12/2012	Yes